Arvinas' Series B Round

Arvinas raised a round of funding on October 21, 2015.

Arvinas (NASDAQ: ARVN) is a pharmaceutical company focused on developing new small molecules aimed at degrading disease-causing cellular proteins. The company is translating these protein degradation …

Articles about Arvinas' Series B Round: